DECISION SUPPORT SYSTEM (DSS) FOR MOLECULAR RADIOTHERAPY BASED ON DIGITAL PATIENTS (Q2035310): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claims)
(‎Changed an Item: The budget was changed)
Property / budget
 
364,566.99 Euro
Amount364,566.99 Euro
UnitEuro
Property / budget: 364,566.99 Euro / rank
 
Normal rank
Property / EU contribution
 
181,685.97 Euro
Amount181,685.97 Euro
UnitEuro
Property / EU contribution: 181,685.97 Euro / rank
 
Normal rank
Property / co-financing rate
 
49.84 percent
Amount49.84 percent
Unitpercent
Property / co-financing rate: 49.84 percent / rank
 
Normal rank

Revision as of 09:05, 12 February 2022

Project Q2035310 in Italy
Language Label Description Also known as
English
DECISION SUPPORT SYSTEM (DSS) FOR MOLECULAR RADIOTHERAPY BASED ON DIGITAL PATIENTS
Project Q2035310 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    181,685.97 Euro
    0 references
    budget
    364,566.99 Euro
    0 references
    co-financing rate
    49.84 percent
    0 references
    start time
    13 December 2016
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    UNIVERSITA' DEGLI STUDI DI ROMA LA SAPIENZA
    0 references
    KAY SYSTEMS ITALIA SRL
    0 references
    beneficiary
    Q268802
    0 references
    Q282208
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    LA RADIOTERAPIA MOLECOLARE, INDICATA IN MOLTE NEOPLASIE, IMPIEGA RADIONUCLIDI COME SORGENTI NON SIGILLATE (SPESSO RADIOFARMACI) PER RILASCIARE RADIAZIONI E DISTRUGGERE CELLULE NEOPLASTICHE. (Italian)
    0 references
    THE MOLECULAR RADIOTHERAPY, REFERRED TO IN MANY CANCERS, USES RADIONUCLIDES AS NON-SEALED SOURCES (OFTEN RADIOPHARMACEUTICALS) TO RELEASE RADIATION AND DESTROY NEOPLASTIC CELLS. (English)
    0 references
    LA RADIOTHÉRAPIE MOLÉCULAIRE, INDIQUÉE DANS DE NOMBREUX NÉOPLASMES, UTILISE LES RADIONUCLÉIDES COMME SOURCES NON SCELLÉES (SOUVENT RADIOPHARMACEUTIQUES) POUR LIBÉRER LE RAYONNEMENT ET DÉTRUIRE LES CELLULES NÉOPLASIQUES. (French)
    point in time
    16 December 2021
    0 references
    MOLECULAIRE RADIOTHERAPIE, GEÏNDICEERD IN VEEL NEOPLASMA’S, GEBRUIKT RADIONUCLIDEN ALS NIET-VERZEGELDE BRONNEN (VAAK RADIOFARMACEUTICA) OM STRALING VRIJ TE GEVEN EN NEOPLASTISCHE CELLEN TE VERNIETIGEN. (Dutch)
    point in time
    23 December 2021
    0 references
    MOLEKULARE STRAHLENTHERAPIE, DIE IN VIELEN NEOPLASMEN ANGEZEIGT WIRD, VERWENDET RADIONUKLIDE ALS NICHT VERSIEGELTE QUELLEN (OFT RADIOPHARMAZEUTIKA), UM STRAHLUNG FREIZUSETZEN UND NEOPLASTISCHE ZELLEN ZU ZERSTÖREN. (German)
    point in time
    24 December 2021
    0 references
    LA RADIOTERAPIA MOLECULAR, INDICADA EN MUCHAS NEOPLASIAS, UTILIZA RADIONUCLEIDOS COMO FUENTES NO SELLADAS (A MENUDO RADIOFÁRMACAS) PARA LIBERAR RADIACIÓN Y DESTRUIR CÉLULAS NEOPLÁSICAS. (Spanish)
    point in time
    25 January 2022
    0 references
    location (string)
    ROMA
    0 references

    Identifiers

    Italian Unique Project Code
    F87H18000440007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035310&oldid=27872482"